ABL Tyrosine Kinase Inhibitors Linked to Arterial Thrombosis – Blood Journals Portfolio
Blood Journals Portfolio shared a post on LinkedIn about a recent article by Richard Travers et al, published in Blood VTH:
”Another important study in observance of Deep Vein Thrombosis Awareness Month, focusing on Arterial Thrombosis.
‘Distinct endothelial cell toxicities of Abl tyrosine kinase inhibitors lead to arterial thrombosis’ published on January 7, 2026, concluded that Dasatinib, ponatinib, and nilotinib damage ECs in different ways, all of which can contribute to arterial thrombosis.”
Title: Distinct endothelial cell toxicities of Abl tyrosine kinase inhibitors lead to arterial thrombosis
Authors: Richard Travers, Alec Stepanian, Sebastiana Redford, Gregory Martin, Nicole L. Svedberg, Kun Xu, Glenn Merrill-Skoloff, Christopher Chen, Robert Flaumenhaft, Iris Z. Jaffe
Read the Full Article on Blood VTH

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 17, 2026, 10:41Elena Petkovic։ Highlights from the ISBT–WHO Plasma Management Workshop
-
Nov 17, 2026, 10:30Cheng-Hock Toh: Haematology Is Everywhere – But Is It Recognised?
-
Nov 17, 2026, 10:23Akshat Jain: The Importance of Knowing Your Sickle Cell Status
-
Nov 17, 2026, 10:12Caitlin Raymond: What Does Apheresis Really Cost?
-
Nov 17, 2026, 05:47Multidisciplinary Teams Kick Off SAHF MASAC ES 2026 with Pre-Symposium Workshops – South African Haemophilia Foundation
-
Nov 17, 2026, 05:41Boitumelo Malatji: South African Delegation Advances Advocacy Strategies at NNHF Southern Africa Workshop
-
Nov 17, 2026, 05:36Joining the PACTA Uganda Mental Health and Addiction Community Camp 2026 – Tackle Sickle Cell Africa
-
Nov 17, 2026, 05:30Nathan Connell: Women’s Hematology Summit 2027 to Address Hematologic Health Across the Lifespan
-
Nov 17, 2026, 05:25Mane Kurghinyan: Representing Armenia and HemAI Dynamics at the Falling Walls Lab Global Finale 2026